Market Overview

J.P. Morgan Reiterates Overweight Rating, $26 PT on Insulet Corporation on Updated Estimates

Share:
Related PODD
Oppenheimer Reiterates Rating, Lowers Price Target On Insulet As New Management Begins Executing Plan
Mid-Morning Market Update: Markets Jump; Family Dollar Profit Misses Estimates
Stocks Targeting Stem Cell and Related Therapies for Diabetes (NVO, PODD & ORGS) (Small Cap Network)

In a report published Friday, J.P. Morgan reiterated its Overweight rating and $26.00 price target on Insulet Corporation (NASDAQ: PODD).

J.P. Morgan noted, “Insulet manufactures the OmniPod insulin pump system, which is a wireless, tubing-free alternative to traditional pump therapy primarily targeting Type I diabetics. We view Insulet as uniquely positioned with a differentiated offering in an under-penetrated market. Awareness of the OmniPod system continues to increase, with revenues projected to grow over 20% through 2015. Insulet recently received approval for the company's next-generation Pod, which is 30% smaller and 25% lighter, which should drive continued sales growth along with margin expansion over the next several years.”

Insulet Corporation closed on Thursday at $21.61.

Latest Ratings for PODD

DateFirmActionFromTo
Jan 2015Leerink SwannMaintainsOutperform
Jan 2015JP MorganDowngradesOverweightNeutral
Jan 2015JefferiesMaintainsBuy

View More Analyst Ratings for PODD
View the Latest Analyst Ratings

Posted-In: J.P. MorganAnalyst Color Reiteration Analyst Ratings

 

Related Articles (PODD)

Around the Web, We're Loving...

Get Benzinga's Newsletters